Abstract library

15 results for "debulking".
#1336 Resection of the Primary Tumor Prior to Peptide Receptor Radionuclide Therapy Improves Treatment Response and Progression-free Survival in Pancreatic Neuroendocrine Tumors with Unresectable Liver Metastases
Introduction: A low burden of disease represents an independent favorable prognostic factor of response to peptide receptor radionuclide therapy (PRRT) in patients affected by gastro-entero-pancreatic neuroendocrine tumors. However it is not clear whether this is due to a lower diffusion of the disease or thanks to debulking surgery
Conference: 13th Annual ENETS conference (2016)
Category: Surgical treatment
Presenting Author: MD Emilio Bertani
Authors: Bertani E, Fazio N, Grana C, Bodei L, ...
#816 Resection at Diagnosis of the Primary Pancreatic Neuroendocrine Tumor in Patients with Unresectable Liver Metastases. A Possible New Approach for a Multimodal Treatment
Introduction: Pancreatic neuroendocrine tumors (PNETs) present in more than 50% of cases with liver metastases as the only systemic localization. Liver metastases are unresectable in 80% of cases at diagnosis. In the context of metastatic disease, the benefit of primary tumor removal in terms of survival is controversial
Conference: 11th Annual ENETS Conference (2014)
Category: Surgical treatment
Presenting Author: Emilio Bertani
#893 The Role of Primary Resection and Hepatic Resection in the Management of Metastatic Pancreatic Neuroendocrine Tumors with Irresectable Liver Metastases
Introduction: More than 40% of pancreatic neuroendocrine tumor (PNET) patients have liver metastases (LM) at diagnosis. Whilst it is agreed that, where possible, curative surgery offers the best outcomes, the role of debulking surgery in the context of irresectable LM remains unclear.
Conference: 11th Annual ENETS Conference (2014)
Category: Surgical treatment
Presenting Author: Mr Logan E Mills
Keywords: liver
#137 Extensive ""multitasking"" surgery for advanced neuroendocrine tumors is safe and effective
Introduction: Management of advanced NETs is controversial, related to degree of intervention; the pendulum is swinging towards a more aggressive interventional approach. Our Center's philosophy is to offer a systematic, planned multimodality treatment for patients with advanced NETs.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: MD MICHAIL K Shafir
#546 Treatment of Malignant Neuroendocrine Tumors of the Hepatopancreatododenal Region
Introduction: The incidence of malignant NETs of the hepatopancreatoduodenal region is currently set at 10-15 cases per 100,000 people. Patient treatment and prognosis differ from those with adenocarcinoma.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Ivan Vasiliev
#835 Surgical Management of the Patients with Liver Metastases of Pancreatic Neuroendocrine Tumors
Introduction: Most pancreatic neuroendocrine tumors (PNET) grow slowly but around 60% of the patients have distant metastases. Although new drugs have recently emerged, surgical resection is still one of the key modalities for curing the tumor.
Conference: 11th Annual ENETS Conference (2014)
Category: Surgical treatment
Presenting Author: M.D., Ph.D. Toshihiko Masui
#25 Predictors of response to radio-embolization (TheraSphere ®) treatment of neuro-endocrine liver metastasis
Introduction: Neuroendocrine tumors (NET) frequently metastasize to the liver. Most patients have diffuse, and therefore incurable, disease. NET liver metastasis has been shown to respond to yttrium-90 microspheres therapy. This study aims to define factors that predict response to radio-embolization in patients with NET liver metastases.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Mazen Hassanain
#102 Presentation and outcome of pancreaticoduodenal tumors in Multiple Endocrine Neoplasia type 1 (MEN 1) syndrome
Introduction: Multiple endocrine neoplasia type 1 (MEN 1) is a rare autosomal dominant condition characterized by the development of parathyroid, pancreaticoduodenal endocrine and pituitaty tumors. Pancreaticduodenal endocrine tumors (PDETs) are a frequent manifestation of MEN 1, with a prevalence ranging from 30 to 75%, and represent a major cause of death in one-third of patients. There is continuing debate on their management, mainly on the optimal surgical strategy, due to their multicentricity and high recurrence rate.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: MD Maria Vittoria Davi'
#412 Single Institutional Series of Neuroendocrine Tumors Managed in the Australian Capital Territory
Introduction: Neuroendocrine tumors (NETs) have been regarded as indolent tumors with significantly variable clinical behavior. Limited information is available on long-term clinical outcome and clinically applicable prognostic factors.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Laeeq Malik
Authors: Malik L, Chua Y, Yip D, Butt N, ...
#566 A Case Report of a Patient with Metastatic Cervical Paraganglioma Responding to the Tyrosine Kinase Inhibitor Sunitinib
Introduction: Paragangliomas are rare neuroendocrine neoplasms that arise from neural crest cells, and are associated with increased expression of angiogenic growth factors. There have been isolated case reports describing potential efficacy with Sunitinib, a tyrosine kinase inhibitor.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Olga Oikonomidou